Compare Heron Therapeutics Inc (HRTX) vs Sherwin-Williams Company (The) Common Stock (SHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Sherwin-Williams Company (The) Common Stock — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $74.18M), while Sherwin-Williams Company (The) Common Stock trades at $327.77 (market cap $78.78B). The key difference: Sherwin-Williams Company (The) Common Stock is far larger — about 1062× Heron Therapeutics Inc's market cap, and Sherwin-Williams Company (The) Common Stock pays a 0.99% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | SHW | |
|---|---|---|
Market Cap | $74.18M | $78.78B |
Volume | 1,857,401 | 1,403,311 |
Sector | Health | Basic Materials |
52-Week High | $1.49 | $372.60 |
52-Week Low | $0.27 | $293.00 |
Typical Hold Time | 36 Days | — |
Enterprise Value | $180.92M | $92.71B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3906, down 6.02% today, with a bullish technical signal from moving averages and oscillators. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates. Despite a high gross margin of 70.07%, it posted a net loss of -$20.20 million in 2025. Analyst consensus is strongly positive with 17 buy ratings. Recent news highlights earnings results and competitive comparisons.
The outlook remains speculative given persistent losses and negative ROE, but strong analyst support and improving cash flow trends offer potential upside. Key risks include profitability challenges and revenue volatility. Investors should weigh the bullish sentiment against fundamental weaknesses.
Sherwin-Williams (SHW) trades at $324.10, up 1.21% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows neutral technical signals but maintains robust fundamentals with 65.12% ROE and expanding manufacturing capacity. Recent facility expansions in Statesville enhance production capabilities, positioning the company for continued market share gains.
Outlook remains positive with analyst consensus at Buy (57.9%) and $383.64 price target, though high valuation multiples (P/E 29.9) and competitive pressures present risks. Earnings growth and strategic investments support upside potential, while margin compression and economic sensitivity warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Sherwin-Williams Company (The) Common Stock
The Sherwin-Williams Company manufactures, develops, and distributes paints, coatings, and related products through three segments: Paint Stores Group, operating more than 4,900 company-owned stores selling Sherwin-Williams-branded products; Consumer Brands Group, selling brands such as Valspar, Dutch Boy, Krylon, and Minwax through mass merchandisers and home centers; and Performance Coatings Group, supplying industrial, construction, and transportation coatings in more than 120 countries.
Read more on SHW →
